Could an asthma drug shield knees from arthritis after ACL surgery?

NCT ID NCT04572256

Recruiting now Disease control Sponsor: Austin V Stone Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial investigates whether montelukast, a common asthma medication, can reduce inflammation and prevent cartilage breakdown after anterior cruciate ligament (ACL) reconstruction. The study enrolls adults aged 25 to 50 who also have a meniscus tear, a group at high risk for rapid osteoarthritis. Participants take either montelukast or a placebo daily for six months after surgery, and researchers measure markers of inflammation and cartilage health using blood tests, MRI scans, and patient questionnaires.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: montelukast (Singulair)
What this could lead to: If it works, this could point toward a simple, inexpensive way to prevent post-traumatic osteoarthritis after ACL surgery.
What could go wrong: This is a very early, small trial (30 people) testing a drug not originally designed for joints. The results may not lead to a proven treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACL INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Anterior Cruciate Ligament Injuries osteoarthritis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACL INJURY MENISCUS TEAR POST-TRAUMATIC OSTEOARTHRITIS

Contacts and locations

Locations

UK Healthcare at Turfland
RECRUITING

Lexington, Kentucky, 40504, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.